drugset / Trial / NCT02263638
Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study
NaSingle-groupOpen-labelTreatment
Summary
Treatment of refractory hemochromatosis rheumatism by Anakinra. Prospective, multicenter, non-randomised, single-arm, open-label, phase II trial.
Timeline
- Start
- 2015-02-04
- Primary completion
- 2018-09-04
- Completion
- 2018-09-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anakinra | Protein / enzyme biologic | 100 mg | Subcutaneous |